ScreenerHero

VERAVera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · veratx.com
32.28USD0.00%Mkt Cap: 2.33B $P/E: —

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a ful…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.33B $
Enterprise Value1.83B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-299.62M $
Revenue/Share—
Last Price32.28 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees361
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.08
PEG—
EV/EBITDA-4.41
EV/Revenue—
P/S—
P/B5.52
EPS (TTM)-5.68
EPS (Forward)-4.41
52W Range
21.1532% of range56.05
52W High56.05 USD
52W Low21.15 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-49.56%
ROA-40.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-241.10M $
CapEx (TTM)630.00K $
FCF Margin—
FCF Yield-9.16%
Net Debt-422.26M $
Net Debt/EBITDA1.02
Balance Sheet
Debt/Equity0.13
Current Ratio10.92
Quick Ratio10.41
Book Value/Sh5.667 USD
Cash/Share6.927 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)77.14 USD
Upside (mean)+139.0%
Target Range34.00 USD – 100.00 USD
$34.00+139.0% to mean$100.00
# Analysts14
Ownership
Shares Out.72.06M
Float52.39M
Insiders0.95%
Institutions117.96%
Short Interest
Short Ratio6.6d
Short % Float24.14%
Short % Out.21.21%
Shares Short15.28M
Short (prev mo.)13.52M
Technical
SMA 5036.13 (-10.7%)
SMA 20039.03 (-17.3%)
Beta0.95
S&P 52W Chg18.16%
Avg Vol (30d)1.89M
Avg Vol (10d)1.98M
Technical Indicators
RSI (14)45.4
MACD-1.4846
MACD Signal-1.7405
MACD Hist.+0.2559
BB Upper35.99 USD
BB Middle32.20 USD
BB Lower28.41 USD
BB Width23.55%
ATR (14)1.940 USD
Vol Ratio (20d)0.64x